Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro
- PMID: 8657573
- PMCID: PMC145861
- DOI: 10.1093/nar/24.10.1908
Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro
Abstract
A target RNA/DNA-specific nuclease could be constructed if a specific RNA/DNA binding domain allowing target RNA/DNA recognition was fused to a (deoxy)ribonucleolytic domain allowing target RNA/ DNA cleavage. The design and construction of such a chimeric enzyme could be of value for both basic research involving structure-function relationships and applied research requiring inactivation of harmful RNA/DNA molecules of cellular or pathogenic origin. The feasibility of this designer nuclease approach for inactivating specific RNA/DNA molecules was assessed using human immunodeficiency virus type-1 (HIV-1) RNA as a model. Trans-activator of transcription (Tat) protein is one of the key regulatory proteins encoded by HIV-1. It binds to the trans-activation-responsive (TAR) RNA element located within the 5' non-coding region of HIV-1 RNAs. The TAR RNA binding domain of this protein was fused to the ribonuclease (RNase) H domain of HIV-1 reverse transcriptase (RT). RNase H by itself lacks an RNA binding domain. The chimeric Tat-RNase H protein was shown to specifically recognize and cleave HIV-1 TAR RNA in vitro. Cleavage was abolished by mutations in the Tat binding region within the TAR RNA, indicating that it is specific to HIV-1 TAR RNA.
Similar articles
-
Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.Nature. 1990 Jun 14;345(6276):640-2. doi: 10.1038/345640a0. Nature. 1990. PMID: 2190099
-
Site-specific cleavage of the transactivation response site of human immunodeficiency virus RNA with a tat-based chemical nuclease.Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3526-30. doi: 10.1073/pnas.89.8.3526. Proc Natl Acad Sci U S A. 1992. PMID: 1565648 Free PMC article.
-
Refolded HIV-1 tat protein protects both bulge and loop nucleotides in TAR RNA from ribonucleolytic cleavage.Biochemistry. 1991 Aug 13;30(32):8060-6. doi: 10.1021/bi00246a026. Biochemistry. 1991. PMID: 1868081
-
RNA recognition and regulation of HIV-1 gene expression by viral factor Tat.Biochemistry (Mosc). 1998 May;63(5):489-503. Biochemistry (Mosc). 1998. PMID: 9632883 Review.
-
Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA.Arch Biochem Biophys. 1999 May 15;365(2):175-85. doi: 10.1006/abbi.1999.1206. Arch Biochem Biophys. 1999. PMID: 10328810 Review.
Cited by
-
Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies.Nucleic Acids Res. 2010 Mar;38(5):1596-609. doi: 10.1093/nar/gkp1145. Epub 2009 Dec 9. Nucleic Acids Res. 2010. PMID: 20007602 Free PMC article.
-
HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins.Mol Ther Nucleic Acids. 2018 Dec 7;13:347-364. doi: 10.1016/j.omtn.2018.09.003. Epub 2018 Sep 11. Mol Ther Nucleic Acids. 2018. PMID: 30340139 Free PMC article. Review.
-
Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor.Mol Ther Nucleic Acids. 2017 Dec 15;9:132-144. doi: 10.1016/j.omtn.2017.08.017. Epub 2017 Sep 21. Mol Ther Nucleic Acids. 2017. PMID: 29246292 Free PMC article.
-
Creating a ribonuclease T-tat that preferentially recognizes and hydrolyzes HIV-1 TAR RNA in vitro and in vivo.Nucleic Acids Res. 2008 Feb;36(3):963-9. doi: 10.1093/nar/gkm1118. Epub 2007 Dec 17. Nucleic Acids Res. 2008. PMID: 18086702 Free PMC article.
-
Current progress and challenges in HIV gene therapy.Future Virol. 2011 Nov 1;6(11):1319-1328. doi: 10.2217/fvl.11.113. Future Virol. 2011. PMID: 22754586 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources